- ANGLE plc (AIM: AGL) unveiled new findings at EACR 2025, demonstrating a unique DNA dual analysis workflow for lung cancer profiling.
- The study identified that 53% of mutations were exclusively in circulating tumor cells (CTCs), highlighting the system's high sensitivity.
- Key druggable mutations discovered include CHEK2, ESR1, NTRK1, and RET, aligning with therapies from major pharmaceutical companies.
ANGLE plc, a notable name in liquid biopsy technology, recently presented breakthrough data at the European Association for Cancer Research (EACR) 2025 conference. The company's innovative dual DNA analysis workflow, which integrates their Parsortix system with Illumina's NextSeq2000 platform, showcased a comprehensive approach to liquid biopsy profiling in lung cancer patients.
In a study involving 27 lung cancer patients, ANGLE's technology differentiated between circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), employing a 79-gene lung cancer panel. Notably, the research revealed a high sensitivity in detecting clinically significant mutations, with 53% of mutations found solely in CTCs, 36% exclusively in ctDNA, and 11% present in both.
These findings underscore ANGLE's capability to identify actionable mutations through CTC-DNA analysis. The study pinpointed specific mutations in genes such as CHEK2, ESR1, NTRK1, and RET, corresponding to targeted treatments from leading pharma companies, including AstraZeneca, Pfizer, and Eli Lilly.
This dual analysis approach, which enables comprehensive molecular profiling from a single blood sample, offers a significant advantage by providing a more extensive view of tumor genetics. This methodology is poised to enhance drug discovery, patient stratification, and clinical trial outcomes, minimizing the reliance on invasive tissue biopsies.
